Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support

American Journal of Hematology

Volumn 86, Issue 3, 2011, Pages 245-250

  Pereira, Arturo ^a   Nomdedeu, Meritxell ^a   Aguilar, Josep Lluís ^a   Belkaid, Mohamed ^a   Carrió, Anna ^a   Cobo, Francesc ^a   Costa, Dolors ^a   Rozman, María ^a   Sanz, Cristina ^a   Nomdedeu, Benet ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951888693     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21959     Document Type: Article

References (33)

1. Tefferi A, Vardigan JW. Mechanisms of disease-Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
2. Stone RM. How I treat patients with myelodysplastic síndromes. Blood 2009; 113: 6296-6303.
3. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
4. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic sindromes. J Clin Oncol 2007; 25: 3503-3510.
5. Cermak J, Kacirkova P, Mikulenkova D, Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009; 33: 1469-1474.
6. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2010; 95: 476-484.
7. Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev 2008; 22 ( Suppl 2): S29-S34.
8. Remacha AF, Arrizabalaga B, Del Cañizo C et al. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 2010; 89: 147-154.
9. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: More than meets the eye? Blood 2009; 114: 5251-5255.
10. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-494.
11. Armand P, Kim H, Cutler C, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
12. Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
13. Suzuki T, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure síndromes. Int J Hematol 2008; 88: 30-35.
14. Mittelman M, Lugassy G, Merkel D, et al. Iron chelation therapy in patients with myelodysplastic syndromes: Consensus conference guidelines. IMAJ 2008; 10: 374-376.
15. Malcovati L. Red bood cell transfusion therapy and iron chelation in patients With myelodysplastic syndromes. Clin Lymph Myeloma 2009; 9 ( Suppl 3): S305-S311.
16. Steensma DP. Myelodysplasia paranoia: Iron as the new radon. Leuk Res 2009; 33: 1158-1163.
17. Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndrome-Cui bono? Leukemia 2009; 23: 1373.
18. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
19. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
20. MacKinnon DP, Krull JL, Lockwood CM. Equivalence of the mediation, confounding and suppression effect. Prev Sci 2000; 1: 173-181.
21. * magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Hematologica 2008; 93: 1385-1388.
22. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971; 51: 209-221.
23. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 2007; 26: 2389-2430.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974; 19: 716-723.
25. Judd CM, Kenny DA. Process Analysis: Estimating mediation in treatment evaluations. Evaluation Rev 1981; 5: 602-619.
26. Coviello VBN. Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4: 103-112.
27. Jann B. Splitting time-span records with categorical time-varying covariates. Stata J 2004; 4: 221-222.
28. Oliva EN, Dimitrov BD, Benedetto F et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 2005; 29: 1217-1219.
29. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28: 2847-2852.
30. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006; 91: 1588-1590.
31. Chee CE, Steensma DP, Wu W et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83: 611-613.
32. Vamvakas EC, Blachman MA. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction? Blood 2001; 97: 1180-1195.
33. Tinmouth A, Fergusson D, Yee IC, Hébert PC. Clinical consequences of red cell storage in the critically ill. Transfusion 2006; 46: 2014-2027.